Introduction
Oral cancers are the 6th most common human neoplasms accounting for 3% of all newly diagnosed cancers[1], with about 300,000 new cases being diagnosed every year worldwide [2, 3]. Despite efforts to improve the survival rates, these have basically remained unchanged for the last 20 years. Since 50 to 70% of patients die within 5 years due to local recurrence, invasion or metastasis to the cervical lymph nodes and/or lung, or second primary cancers, generally elsewhere in the oral cavity (in line with the ‘field cancerization’ theory), the prognosis is poor. Moreover, oral cancers have a severe impact on the quality of life of patients and survivors. In spite of the clinical importance, we are far away from having a complete understanding of the molecular mechanisms of initiation and progression of oral cancers.

The main accepted risk factors are tobacco usage and alcohol consumption but recently, human papillomaviruses (HPV) have also been postulated to play roles [4-6]. While more than 95% of cervical squamous cell carcinomas are linked to persistent HPV infection, the presence of the HPV genome in oral cancers is reported to range from 10 to 70%, depending on the area, the ethnicity of the patients, the type of
Human oral carcinogenesis in vitro

specimen and the detection method [4]. Several studies have provided evidence that chronic infection in basal cells of the oral mucosa with high-risk HPVs, especially type 16 and 18, can promote oral carcinogenesis [7]. Two viral oncoproteins, E6 and E7, are thought to contribute to tumor progression by inactivating p53 and retinoblastoma tumor suppressor (pRB), respectively [8, 9]. E6 facilitates the degradation of p53 through its association with an accessory protein, E6-AP, a component of the ubiquitin proteolytic pathway [9]. E7 proteins of the high-risk types bind to pRB [10], leading to altered activity of this cell-cycle regulator. However, epidemiological studies and experimental data indicate that the viral presence is not enough to induce cancers even in the cervix and the requirement of additional cellular factors are especially suggested in the case of oral carcinogenesis, the roles of HPV are still under estimation.

More than 90% of oral cancers are histopathologically squamous cell carcinomas (SCCs). The development of oral squamous cell carcinomas (OSCCs) is a multistep process, starting from hyperplasia and dysplasia, and finally progressing to neoplasms (benign and malignant) [11, 12]. During these steps, multiple genetic alterations may occur, including chromosomal aberrations, DNA mutations, amplification or deletions and/or epigenetic alterations. Numerous studies have revealed that oncogenes such as EGFR, ERBB2, HRAS, KRAS, and c-MYC (MYC) are often activated by overexpression, amplification, and/or mutation [1, 13-20]. As with other carcinomas, telomerase activation is also common in oral cancers [21, 22]. In addition, mutations of p53 and disruption of the pRB pathway (p16<sup>INK4a</sup>-CDK4/cyclin D1-pRB) are frequently observed [23-27]. Although such genetic changes have been identified, how they individually contribute to oral carcinogenesis has yet to be clarified in detail.

Recently, we have established in vitro multi-step carcinogenesis models for cervical cancer and epithelial ovarian cancer, respectively with and without HPV16 E6/E7 as transgenes [28, 29]. In the present study, taking advantage of this background, we could successfully induce tumorigenic transformation of normal human tongue keratinocytes with defined genetic elements so as to establish in vitro multistep carcinogenesis models for both HPV-positive and -negative OSCCs.

Materials and methods

Isolation of human tongue keratinocytes (HTKs)

Tongues were obtained from two tongue mucoccele patients undergoing cystectomy at Hyogo College of Medicine Hospital, Japan. The Ethics Committee of Hyogo College of Medicine and National Cancer Center approved this study and the subjects gave informed consent for participation. The tongues were grossly normal and no pathological lesions were observed on subsequent histological examination. After collagenase digestion under aseptic conditions, HTK cells were obtained by scraping with a surgical blade and maintained in Epilife (Invitrogen, Carlsbad, CA).

Viral vector construction and viral transduction

Construction of the retroviral expression vectors, pCLXSN-16E6E7, pCLXSH-TERT, pCMSCVpuro-MYC, -MYC<sup>T58A</sup>, pCMSCVbsd-MYC, -MYC<sup>T58A</sup>, pCMSCVbsd-HRAS<sup>G12V</sup>, pCMSCVbsd was described previously [28-30]. Wild type EGFR (EGFR<sup>WT</sup>) and a constitutive active form of EGFR (EGFR<sup>d746</sup>-<sup>750</sup>; deletion from E746 to A750) generated by site-directed mutagenesis were similarly recombined with the retroviral vector pDEST-PQCXIP by the LR reaction (Invitrogen) to generate pQCXIP-EGFR<sup>WT</sup> and pQCXIP-EGFR<sup>d746</sup>-<sup>750</sup>. The production of recombinant retroviruses was as described previously [31]. Construction of lentiviral vectors, CSII-CMV-TERT, CSII-CMV-cyclin D1, CSII-CMV-CDK4<sup>S</sup> and CSII-CMV-DNp53 and the production of recombinant lentiviruses with the vesicular stomatitis virus G glycoprotein (VSV-G) were as described earlier [29, 32]. Following the addition of recombinant viral fluid to cells in the presence of 4 mg/ml polybrene, infected cells were selected in the presence of 50 mg/ml of G418, 1 mg/ml of puromycin, 1 mg/ml of blasticidin-S or 50 mg/ml of hygromycin-B.

Telomerase activity

Telomerase activity was detected using a non-radioisotopic method with a TRAP-eze telomerase detection kit (Intergen, Burlington, MA), as previously described [33].

Western blot analysis

Western blotting was conducted as described previously [33]. Antibodies against cyclin D1...
Human oral carcinogenesis in vitro

(clone G124-326), CDK4(clone 97), p16INK4a (clone G175-405; BD Biosciences, Franklin Lakes, NJ), p53 (clone D0-1; Merck, Darmstadt, Germany), p21WAF1 (12D1; Oncogene Research Products, Cambridge, MA), MYC (sc-42), β-actin (sc-1616; Santa Cruz, CA), HPV16 E6 (clone 47A4)[34], HPV16 E7 (clone 8C9; Invitrogen) and keratin 14 (AF14; Covance, Princeton, NJ) were used as probes, and horseradish peroxidase-conjugated anti-mouse, anti-rabbit (Jackson Immunoresearch Laboratories, West Grove, PA) or anti-goat (sc-2033; Santa Cruz) immunoglobulins were employed as secondary antibodies.

Colony formation in soft agar (anchorage-independent growth)

Cells were seeded at 5×10⁴ cells per 35-mm plate (BD Biosciences) in Epilife with 0.4 % agarose. Colonies over 50µm in diameter were counted after a lapse of 3 weeks. Five photographs of randomly selected areas in each dish were taken at the magnification of ×40. The numbers of colonies were measured with the COLONY program (Fujifilm, JAPAN). The experiments were performed in triplicate.

Tumorigenesis in nude mice

All surgical procedures and care administered to the animals were in accordance with institutional guidelines. Cells were resuspended in 50% Matrigel (BD Biosciences) and injected subcutaneously into a flank or orthotopically into female 6 to 7-week old BALB/c nude mice (Clea Japan Inc., Tokyo, Japan).

Immunohistochemical examination

Formalin-fixed and paraffin-embedded tissue sections (4 micrometer-thick) were deparaffinized in xylene and rehydrated through a series of graded ethanols (100–70%). For antigen retrieval, slides were immersed in a citrate buffer (pH6.4) and heated for 15 minutes in a microwave. The slides were then incubated in methanol containing 0.3% H₂O₂ to inhibit endogenous peroxidase activity. After washing, primary antibody against keratin 14 (1:500, SP53, Spring Bioscience, Pleasanton, CA) was applied for 1 h and binding was detected using an Envision Kit (Dako Cytomation; K4006). Color development was achieved with 3, 3-diaminobenzine (DAB) as chromogen and hematoxylin counterstaining. As a negative control, we used normal non-immune serum from the same source as the primary antibody.

Results

Immortalization of HTK cells with or without viral oncogenes

To establish an in vitro model system for HPV-positive OSCCs, two independent batches of primary HTK cells (HTK1 and HTK3T) were transduced with retroviral vectors expressing HPV16 E6 and E7 (HTK1-E6E7). HTK3 cells were transduced with TERT first since HPV16 E6 and E7 are not sufficient to avoid telomere erosion. Pooled populations of these HTK cells were named HTK1-E6E7 and HTK3-TE6E7, respectively. Expression of the transgenes was confirmed by immunoblotting (Figure 1A). As expected, decreased levels of p53 were observed in these cells (Figure 1A). We have shown that both telomerase activation and inactivation of the p16INK4a/pRB pathway are required for immortalization of human primary epithelial cells. Disruption of the pRB pathway, such as inactivation of p16INK4a and overexpression of cyclin D1, are also frequently observed in OSCCs. In order to establish an in vitro model system for HPV16-negative OSCCs, a mutant form of CDK4 (CDK4R24C), which cannot be inactivated by p16, and cyclin D1 as well as TERT were transduced into HTK cells (HTK1 and HTK3) with lentiviral vectors (Figure 1B). Pooled populations of these HTK cells were named HTK1-K4DT and HTK3-K4DT, respectively. Expression of the transgenes was confirmed by immunoblotting (Figure 1B) and the TRAP assay (Figure 1C). As expected, the combination of HPV16 E6E7 or CDK4R24C, cyclin D1 and TERT resulted in extended life span and virtual immortalization of HTK cells (Figure 1D). Both the primary and immortalized cell lines expressed keratin 14, a marker of keratinocytes (data not shown). HTK1 cells showed normal diploidy and HTK1-K4DT cells was almost diploid though HTK3-K4DT cells tended to be tetraploid with some chromosomal abnormalities.

Combined transduction of HRAS and MYC into HTK1-K4DT-DNp53 and HTK1-E6E7 cells induces anchorage-independent growth and tumor-forming ability in nude mice.

In HPV-negative OSCCs, overexpression of MYC
Human oral carcinogenesis in vitro

and mutation of HRAS and p53 are frequently observed especially in tobacco chewing individuals for HRAS [35]. Thus, a dominant negative form of p53 (DNp53), HRAS_G12V and MYC were serially transduced into HTK1-K4DT cells. Expression of these transgenes together with accumulation of p53 and downregulation of p21_WAF1 was confirmed by immunoblotting (Figure 2A). Then we assessed the effects of oncogenic HRAS_G12V and MYC on cell growth. HTK1-K4DT-DNp53 cells with HRAS_G12V and MYC grew faster than those with an empty vector (Figure 2B), and formed numerous and much larger colonies in soft agar medium than those with HRAS_G12V alone, whereas cells with empty vector formed no colonies (Figure 2C). HTK1-K4DT-DNp53 cells with HRAS_G12V and MYC or a mutant form of MYC (MYC_T58A), which is resistant to proteosomal degradation, formed tumors in nude mice, whereas those without MYC failed to form tumors (Table 1). HTK1-K4DT-HRAS_G12V-MYC cells, which did not express a dominant negative form of p53 developed tumors less efficiently and with a long latent period, while HTK1-K4DT-DNp53 cells with MYC alone did not form tumors (Table 1).

For the HPV-positive OSCC model, we transduced HRAS_G12V and MYC serially into HTK1-E6E7 cells and confirmed expression of transgenes by immunoblotting (Figure 2D). HTK1-E6E7 cells expressing HRAS_G12V and MYC or HRAS_G12V alone grew faster than those with empty vectors (Figure 2E). HTK1-E6E7 cells expressing HRAS_G12V and MYC formed numerous large colonies and those expressing HRAS_G12V alone formed some small colonies, whereas those with empty vectors formed no colonies.
Human oral carcinogenesis in vitro

(Figure 2F), HTK1-K4DT-HRASG12V-MYC cells (3/4) as well as HTK1-E6E7-HRASG12V-MYC cells formed tumors (8/8) in nude mice, whereas those expressing MYC alone failed to do so (Table 1). This is consistent with our previous results that a combination of E6E7 and oncogenic HRAS without MYC can confer tumorigenicity on human cervical keratinocytes and MYC substantially enhances the tumorigenicity. These results indicate that a combination of oncogenic HRAS and MYC can cooperatively confer anchorage-independent growth and tumorigenicity on HTK cells expressing either E6E7 or CDK4/cyclin D1/TERT and DNp53.

Combined transduction of a constitutively active form of EGFR and a degradation-resistant form of MYC into HTK1-K4DT-DNp53 and HTK1-E6E7 cells induces anchorage-independent growth and tumor-forming ability in nude mice

Excluding cases in tobacco chewers, overexpression of EGFR or activating mutations of EGFR are observed more frequently than activating mutations in the RAS oncogenes [17, 35]. To determine a role of enhanced EGFR signaling in the development of OSCCs, wild type EGFR (EGFRwt) or a constitutively active form of EGFR (EGFRD746-750) instead of HRAS was transduced into HTK1-K4DT and HTK1-E6E7 cells as expected if HRAS and EGFR are acting in the same pathway. Expression of the transgenes was confirmed by immunoblotting (Figure 3A in HTK1-K4DT and Figure 4A in HTK1-E6E7). Total and the phosphorylated form of EGFR in HTK1-K4DT-DNp53-EGFRWT cells and HSC2
Table 1. Summary of data for tumorigenic potential of HTK1 and HTK3 cells with various transgenes (1×10^6 cells/site).

<table>
<thead>
<tr>
<th>Cells</th>
<th>No. of tumors/Sites of injection</th>
<th>Cells</th>
<th>No. of tumors/Sites of injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTK1-K4DT-DNp53-HRAS512V</td>
<td></td>
<td>HTK3-K4DT-DNp53-HRAS512V</td>
<td></td>
</tr>
<tr>
<td>vector exp 1</td>
<td>0/4</td>
<td>vector</td>
<td>0/4</td>
</tr>
<tr>
<td>exp 2</td>
<td>0/4</td>
<td>MYC56A</td>
<td>4/4 (4)</td>
</tr>
<tr>
<td>MYC56A</td>
<td>4/4 (3)</td>
<td>MYC56A</td>
<td>4/4 (3)</td>
</tr>
<tr>
<td>HTK1-K4DT-DNp53-EGFRWT</td>
<td></td>
<td>HTK3-K4DT-DNp53-EGFRWT</td>
<td></td>
</tr>
<tr>
<td>vector exp 1</td>
<td>0/4</td>
<td>vector</td>
<td>0/4</td>
</tr>
<tr>
<td>exp 2</td>
<td>4/4 (7)</td>
<td>MYC56A</td>
<td>4/4 (9)</td>
</tr>
<tr>
<td>HTK1-K4DT-DNp53-EGFR4746-750</td>
<td></td>
<td>HTK3-K4DT-DNp53-EGFR4746-750</td>
<td></td>
</tr>
<tr>
<td>vector exp 1</td>
<td>0/4</td>
<td>vector</td>
<td>0/4</td>
</tr>
<tr>
<td>exp 2</td>
<td>4/4 (6)</td>
<td>MYC56A</td>
<td>4/4 (4)</td>
</tr>
<tr>
<td>HTK1-K4DT-HRAS512V</td>
<td></td>
<td>HTK3-T-E6E7-HRAS512V</td>
<td></td>
</tr>
<tr>
<td>vector exp 1</td>
<td>0/4</td>
<td>vector</td>
<td>0/4</td>
</tr>
<tr>
<td>MYC56A</td>
<td>1/4 (5)</td>
<td>MYC56A</td>
<td>0/4</td>
</tr>
<tr>
<td>HTK1-K4DT-DNp53-MYC</td>
<td></td>
<td>HTK3-T-E6E7-EGFRWT</td>
<td></td>
</tr>
<tr>
<td>vector exp 1</td>
<td>3/4 (5)</td>
<td>vector</td>
<td>0/4</td>
</tr>
<tr>
<td>exp 2</td>
<td>4/4 (4)</td>
<td>MYC56A</td>
<td>4/4 (6)</td>
</tr>
<tr>
<td>MYC56A</td>
<td>4/4 (4)</td>
<td>MYC56A</td>
<td>4/4 (6)</td>
</tr>
<tr>
<td>HTK1-E6E7-EGFRWT</td>
<td></td>
<td>HTK3-T-E6E7-EGFR4746-750</td>
<td></td>
</tr>
<tr>
<td>vector exp 1</td>
<td>0/4</td>
<td>vector</td>
<td>0/4</td>
</tr>
<tr>
<td>MYC56A</td>
<td>0/4</td>
<td>MYC56A</td>
<td>0/4</td>
</tr>
<tr>
<td>MYC56A</td>
<td>0/4</td>
<td>MYC56A</td>
<td>0/4</td>
</tr>
<tr>
<td>HTK1-E6E7-EGFR4746-750</td>
<td></td>
<td>HTK3-T-E6E7-MYC</td>
<td></td>
</tr>
<tr>
<td>vector</td>
<td>0/4</td>
<td>vector</td>
<td>0/4</td>
</tr>
<tr>
<td>MYC56A</td>
<td>4/4 (10)</td>
<td>MYC56A</td>
<td>4/4 (9)</td>
</tr>
<tr>
<td>HTK1-E6E7-MYC</td>
<td>0/4</td>
<td>MYC56A</td>
<td>0/4</td>
</tr>
</tbody>
</table>

Incidence of tumor formation within 16 weeks of observation period was scored. Number in parentheses indicates observation period (weeks) when mice were killed because of the faster growth of one or more tumors in the same mouse. Some cell lines were repeatedly established. exp 1, 1st experiment; exp 2, 2nd experiment.

(human OSCC cell line with EGFR amplification) cells were higher than those in vector transduced cells and the phosphorylation levels were further increased by the addition of EGF. As expected, the phosphorylation levels of EGFRWT in EGFRWT expressing cells were much higher without addition of EGF, indicating ligand-independent activation of the EGFRWT (Figure 3A, P-EGFR). Exogenous EGFR expression levels in HTK1-K4DT or HTK1-E6E7 cells were comparable to that of HSC2.

HTK1-K4DT cells expressing EGFRWT or EGFR4746-750 grew faster than those with an empty vector (Figure 3B), and additional transduction of MYC56A only slightly enhanced proliferation in culture (Figure 3B). HTK1-K4DT-DNp53 cells expressing EGFRWT or EGFR4746-750 exhibited anchorage-independent growth, enhanced by additional MYC56A transduction, whereas those with empty vector formed no colonies (Figure 3C). HTK1-K4DT-DNp53 cells expressing EGFRWT or EGFR4746-750 were able to form tumors only when MYC56A was co-expressed (Table 1) and those with EGFRWT (Table 1).

HTK1-E6E7 cells expressing EGFR4746-750 grew faster than those expressing EGFRWT (Figure
Figure 3. Anchorage-dependent and -independent growth of HTK1-K4DT-DNp53 cells. (A) HTK1-K4DT-DNp53 cells were serially infected with retroviruses expressing EGFRWT, EGFRd746-750, MYCT58A or empty vectors (-). After selection, cells were harvested and subjected to SDS-PAGE. Western blots show expression of transgenes. EGFRd746-750; constitutively active mutant of EGFR. Cells were first starved in medium without bovine pituitary extract and EGF for 72 hours and some of them were stimulated with EGF for 30 min before harvesting as indicated. HSC2; human OSCC cell line with EGFR amplification. (B) Growth curves of HTK1-K4DT-DNp53 cells expressing different transgenes as described in (A). (C) Anchorage-independent growth of HTK1-K4DT-DNp53 cells expressing different transgenes performed as for Fig. 2(C). Scale bars, 250 μm.
and showed increased anchorage-independent growth regardless of the exogenous expression of MYC<sup>TS<sub>8A</sub></sup>, though those expressing EGFR<sup>WT</sup> showed poor anchorage-independent growth without MYC<sup>TS<sub>8A</sub></sup> (Figure 4). In tumorigenic assay, HTK1-E6E7 cells expressing EGFR<sup>746-750</sup> cells formed tumors only when MYC or MYC<sup>TS<sub>8A</sub></sup> was co-expressed, whereas those expressing EGFR<sup>WT</sup> did not form tumors even with addition of MYC or MYC<sup>TS<sub>8A</sub></sup> (Table 1).

**Histopathological findings for tumors derived from HTK1 cells.**

Isolated xenograft tumors were examined by histopathologically (Figure 5). HTK1-K4DT-DNp53-HRAS<sup>G12V-MYC<sup>TS<sub>8A</sub></sup></sup> and HTK1-K4DT-DNp53-EGFR<sup>746-750-MYC<sup>TS<sub>8A</sub></sup></sup> tumors mainly comprised poorly differentiated SCCs. On the other hand, tumors of HTK1-E6E7-HRAS<sup>G12V-MYC<sup>TS<sub>8A</sub></sup></sup> and HTK1-E6E7-EGFR<sup>746-750-MYC<sup>TS<sub>8A</sub></sup></sup> MYC<sup>TS<sub>8A</sub></sup> cells were well differentiated SCCs with keratin pearls. Both HTK1-K4DT-DNp53-HRAS<sup>G12V-MYC<sup>TS<sub>8A</sub></sup></sup> and HTK1-E6E7-HRAS<sup>G12V-MYC<sup>TS<sub>8A</sub></sup></sup> cells were positive for keratin 14 proved to be carcinomatous in structure (Figure 5, insets).

**Confirmation of the multi-stage nature of carcinogenesis with the HTK3T cell line.**

It is possible that additional alterations (genetic and/or epigenetic) occurring during the process of introducing oncogenic genes could contribute to their tumorigenic phenotype. To address this possibility, we repeatedly transduced EGFR<sup>WT</sup>, EGFR<sup>746-750</sup> or HRAS<sup>G12V</sup> plus MYC<sup>TS<sub>8A</sub></sup> into HTK3-T66E7 and HTK3-K4DT-DNp53 cells, another independent batch of HTKs derived from a
different patient. All these cells reproducibly developed subcutaneous tumors in nude mice, whereas those transduced with HRAS\(^{G12V}\) alone without MYC\(^{T58A}\) and carrying empty vectors failed to form tumors (Table 1). The histological appearance of HTK3-K4DT-DNp53-HRAS\(^{G12V}\)-MYC\(^{T58A}\) and HTK1-TE6E7-HRAS\(^{G12V}\)-MYC\(^{T58A}\) tumors was similar to that of corresponding tumors with HTK1-K4DT and HTK1-E6E7 (data not shown). These results indicate that the combination of multiple genetic elements we applied can reproducibly fully transform HTK cells.

**Discussion**

Our goal is to develop an appropriate in vitro model for recapitulating development and progression of both HPV-positive and -negative human OSCCs. OSCCs are thought to arise from basal layer epithelial cells of oral mucosa, which regenerates stratified epithelium through terminal differentiation of keratinocytes. The fact that human tongue keratinocytes (HTKs) were here obtained from two patients without smoking histories or cancer, allowed us to explore inter-individual variation in the tumor formation process. In this report, we document establishment of an in vitro model system for HPV16-positive and -negative multistep carcinogenesis using normal HTKs.

As also shown earlier, overexpression of HPV16 E6 and E7 themselves could immortalize HTKs but did not support anchorage-independent growth. We next tried to immortalize HTKs without viral oncogenes to establish an in vitro model system for HPV-negative multistep carcinogenesis. By CDK4 and cyclin D1 transduction in combination with TERT, we here established novel HTK cell lines, termed HTK1-K4DT and HTK3-K4DT. The pRB pathway is frequently disrupted in OSCCs by p16\(^{INK4a}\) inactivation.
and/or abnormal expression of CDK4/cyclinD1 [18, 20, 36, 37]. OSCCs, like many other carcinomas, maintain telomere length with telomerase activation [21, 22]. Immortality is one of the important characteristics of malignancy and ectopic expression of these genes thus could mimic the events that occur during development of OSCCs. Alterations of p53 have been detected in approximately 50% of OSCCs [23, 36-39] and some authors suggest that p53 alterations might represent an early step in the oral carcinogenesis, especially for HPV-negative OSCCs.

OSCCs often overexpress the epidermal growth factor receptor (EGFR) and some of its active variants or harbor activating mutations in the RAS oncogene with a rate ranging from 3% to 5% in Western countries and up to 50% in India and Southeast Asia. Importantly, EGFR mutations and KRAS mutations are mutually exclusively observed in non-small cell lung carcinomas[40]. A similar tendency has also been observed in a smaller number of OSCCs [19]. Recently, complications of chewing betel quid in oral cancer development have been found clinically meaningful and important in India and Southeast Asia. For example, EGFR amplification or a high frequency of mutations in codons 12 and 61 of the HRAS were reported to be associated with heavy betel quid users [16, 35, 37, 41]. EGFR, a key cancer-driving gene during OSCC development, belongs to the type I receptor tyrosine kinase (ERBB) subfamily, and appears more important than other ERBB members for oral cancer development [19]. In addition to gene amplification, activating mutation of genes in kinase signaling pathways is another common genetic event during cancer development. EGFR and its downstream effectors have diverse cellular functions, impacting on cell proliferation, differentiation, motility, survival, and tissue development [42]. The RAS-RAF-MAPK cascade is particularly active when cancer cells overexpress EGFR [43]. Schulze and colleagues have further shown that the majority of RAS-RAF-MAPK-induced changes in gene expression are dependent on the status of EGFR [44], highlighting the critical roles of the signal networking among different oncogenes in cancers [45]. In addition, Raimondi et al have shown that, in spite of ras being likely activated in many K14-expressing squamous epithelia in their animal system, those animals develop benign tumors only in the oral mucosa. This suggests that oral epithelial cells might be particularly sensitive to RAS-induced aberrant cell proliferation. Here, transduction of oncogenic HRAS or wild type EGFR or mutant EGFR (EGFR8746-750) into HTK-E6E7 and HTK-K4DT-DNp53 cells resulted in enhanced anchorage-independent growth but no tumor forming ability, except when oncogenic HRAS was transduced into HTK1-E6E7. Therefore we tried to define essential genetic alterations that cooperate with HRAS812V or wild type EGFR or EGFR8746-750 to induce a fully transformed phenotype. Amplification and/or overexpression of the MYC gene, an oncogene but also a strong inducer of apoptosis, are found in 26-40% of all oral cancers [15, 20]. Furthermore, amplification of MYC is a common finding in advanced stages, which may suggest a critical role in progression. In this study, transduction of wild-type or a mutant MYC strongly enhanced anchorage-independent growth of HTK-E6E7 and HTK-K4DT-DNp53 cells expressing HRAS812V, EGFRWT, or EGFR8746-750, and resulted in tumor formation, except when MYC or MYCT58A was transduced into HTK-E6E7-EGFRWT cells (Table 1). In addition, we have focused on development of an orthotopic model of OSCC through injecting HTK cell lines into the tongues of nude mice. HTK1-K4DT-DNp53-HRAS812V, MYCT58A and HTK1-K4DT-DNp53-EGFRWT, MYCT58A cells formed orthotopic tumors (Figure 6A) and showed SCC-like features histopathologically (Figure 6B). Furthermore, one out of the four tumors yielded regional metastases in 2-3 weeks (data not shown). Further investigation with the orthotopic model should be useful to identify genes and other factors involving in regional metastases.

Human cancer cell lines, even though they are derived from well-differentiated carcinomas, rarely mimic the original histology when inoculated into mice. In our study, HTK1-K4DT-DNp53 cells expressing HRAS812V or EGFR8746-750 and MYC (HPV-negative model) formed tumors faster than HTK1-E6E7 cells expressing the same additional oncogenes (HPV-positive model), and HTK1-E6E7 cells expressing EGFRWT and MYC or MYCT58A failed to form tumors unlike the corresponding HTK1-K4DT-DNp53 cells (Table 1). In addition, isolated subcutaneously xenograft tumors of HTK1-E6E7 cells expressing either HRAS812V plus MYC T58A or EGFR8746-750 -MYCT58A (HPV-positive model) showed histological features of well-differentiated SCCs, but the corresponding
HTK1-K4DT-DNp53 cells (HPV-negative model) did not (Figure 5). These differences of tumorigenicity and histopathology between our HPV-positive and HPV-negative models might reflect the favorable outcome associated with HPV in oropharyngeal cancer [17, 46]. Further efforts to clarify critical pathways in carcinogenesis with each histological subtype should help provide best targets for early detection and effective molecular therapies.

In summary, we newly immortalized primary HTK cells with cellular genes (CDK4, cyclin D1 and TERT) or viral oncogenes (HPV16 E6E7). With these non-tumorigenic cell lines, we have developed for the first time an in vitro culture model faithfully recapitulating the development of HPV-positive and -negative OSCCs with genetically defined elements. Our results provide evidence that either HRAS mutation or activation of EGFR in cooperation with MYC overexpression is a strong set of drivers sufficient for transformation of HTKs which have acquired inactivation of the pRB and p53 pathways and telomerase activation by either HPV16E6E7 or equivalent genetic alterations. Our experimental model should facilitate further studies to understand genesis of OSCCs and hopefully will assist in the evaluation of new therapies.

Acknowledgements

We would like to express our appreciation to Yuki Inagawa, Shin-ichi Ohno and Takako Ishiyama for their expert technical assistance. This work was supported in part by Grants-in-Aid for Cancer Research from the Ministry of Health Labor and Welfare, for Cancer Research from the Yasuda Medical Foundation to T.K., and for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan to Y.Z., K.N., M.U., and T.K.

Conflict of interest

Authors have no conflict of interest.

Address correspondence to: Tohru Kiyono, MD, PhD, Division of Virology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. E-mail: tkiyono@ncc.go.jp

References

Human oral carcinogenesis in vitro


